Advertisement

Topics

Gilead Sciences to acquire Kite Pharma for $11.9B

13:53 EDT 28 Aug 2017 | CentreWatch

Gilead Sciences and Kite Pharma announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash. The transaction, which values Kite at approximately $11.9 billion, was unanimously approved by both the Gilead and Kite Boards of Directors and is anticipated to close in […]

The post Gilead Sciences to acquire Kite Pharma for $11.9B appeared first on CenterWatch News Online.

Original Article: Gilead Sciences to acquire Kite Pharma for $11.9B

NEXT ARTICLE

More From BioPortfolio on "Gilead Sciences to acquire Kite Pharma for $11.9B"

Quick Search
Advertisement
 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...